Importantly, this down-regulation is concurrently associated with increased sensitivity of RCC tumor cells to mTOR inhibitors, suggesting that lactotransferrin may serve as a predictive biomarker for therapeutic response [49]. The gene discussed is LTF; the disease is renal cell carcinoma.